Introduction
COVID-19Tetracyclines, coronavirus disease 2019
VIRUS, CORONAVIRUS DISEASE 2019
Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, the development of vaccines and therapeutic agents has mitigated its severity and mortality. mRNA vaccines, such as BNT162b2 and mRNA-1273In addition to vaccines, antiviral agents, and neutralizing antibodies, which are specific to the SARS-CoV-2 virus, repurposed immunomodulatory agents, such as dexamethasone, balicitinib, tocilizumab, and sarilumab, have been shown to mitigate the severity and mortality of COVID-19Tetracyclines exhibit anti-viral and anti-inflammatory activities through multiple mechanisms